Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
Table 1
Patient baseline characteristics versus metastatic profile in the bone.
Metastasis in bone
Absent (N = 894)
Present (N = 140)
Total (N = 1034)
N (%)
N (%)
N (%)
Intended treatment
Doxorubicin 75 mg/m2
229 (25.6)
32 (22.9)
261 (25.2)
Doxorubicin 75 mg/m2/ifosfamide 10 g/m2
187 (20.9)
33 (23.6)
220 (21.3)
Pazopanib, 800 mg once daily
309 (34.6)
49 (35.0)
358 (34.6)
Trabectedin 1.3 mg/m2, 3 hrs IV
38 (4.3)
6 (4.3)
44 (4.3)
Trabectedin 1.5 mg/m2, 24 hrs IV
33 (3.7)
7 (5.0)
40 (3.9)
Eribulin 1.4 mg/m2 every 3 weeks
98 (11.0)
13 (9.3)
111 (10.7)
Age category
Less than 40
194 (21.7)
31 (22.1)
225 (21.8)
40 to 50
201 (22.5)
42 (30.0)
243 (23.5)
50 to 70
428 (47.9)
60 (42.9)
488 (47.2)
Older than 70
71 (7.9)
7 (5.0)
78 (7.5)
Gender
Male
411 (46.0)
61 (43.6)
472 (45.6)
Female
483 (54.0)
79 (56.4)
562 (54.4)
Tumour grade
Low/intermediate
411 (46.0)
55 (39.3)
466 (45.1)
High
433 (48.4)
79 (56.4)
512 (49.5)
Missing
50 (5.6)
6 (4.3)
56 (5.4)
Line of treatment
1st
488 (54.6)
77 (55.0)
565 (54.6)
2+
406 (45.4)
63 (45.0)
469 (45.4)
Site of primary tumour
Thorax
104 (11.6)
16 (11.4)
120 (11.6)
Abdomen
171 (19.1)
20 (14.3)
191 (18.5)
Extremities
330 (36.9)
54 (38.6)
384 (37.1)
Visceral
194 (21.7)
29 (20.7)
223 (21.6)
Others
94 (10.5)
20 (14.3)
114 (11.0)
Missing
1 (0.1)
1 (0.7)
2 (0.2)
Histology type
Liposarcoma (all subtypes)
92 (10.3)
8 (5.7)
100 (9.7)
Leiomyosarcoma
278 (31.1)
46 (32.9)
324 (31.3)
Angiosarcoma
19 (2.1)
10 (7.1)
29 (2.8)
Synovial sarcoma
129 (14.4)
13 (9.3)
142 (13.7)
Others
376 (42.1)
63 (45.0)
439 (42.5)
Time between histological diagnosis and registration/randomisation
Less than a year
377 (42.2)
60 (42.9)
437 (42.3)
1-2 years
174 (19.5)
29 (20.7)
203 (19.6)
More than 2 years
343 (38.4)
51 (36.4)
394 (38.1)
Performance status
0
494 (55.3)
63 (45.0)
557 (53.9)
1
400 (44.7)
77 (55.0)
477 (46.1)
Treatment regimens in first-line setting: doxorubicin, doxorubicin + ifosfamide, and trabectedin. Treatments regimens for 2nd-line or later treated patients: pazopanib and eribulin.
